APICDMO has the capability to manufacture bulk quantities of Favipiravir API and intermediates, which has GMP and DMF certification, along with complete testing equipment and qaulity management system.
Favipiravir--Application History Worldwide

Japan supplied Favipiravir to affected countries as emergency aid during the Ebola virus epidemic of 2014-16, which claimed over 11,000 lives. The drug was effective in bringing down mortality rates from 30 per cent to 15 per cent when administered to those with low to moderate viral loads, according to an article in Wired. According to a Time report, countries such as Japan and the US built stockpiles of the drug over the years for emergency medication during seasonal flu. The medicine was also stockpiled by the UAE during the MERS epidemic (which is also caused by a coronavirus). The coronavirus continues to wreak havoc worldwide and a cure has yet to be found,but there is another drug that has the scientific world talking, as we all dream of a return to normal life, without living in fear of the deadly disease.The magic drug was favipiravir(CAS: 259793-96-9).
What Is Favipiravir?

Favipiravir is also known as T-705, which is a new type of RNA polymerase inhibitor, was approved in Japan in March 2014 as another weapon for antiviral therapy for influenza A and B. Studies have shown that, in addition to influenza viruses, favipiravir may also exhibit good antiviral effects on a variety of RNA viruses, such as Ebola virus, sand virus, bunya virus, rabies virus, etc. The new coronavirus belongs to the coronavirus, is a positive chain single-stranded RNA virus with a coat membrane, and from the mechanism, favipiravir also has potential antiviral effects on the new coronavirus.
How Does Favipiravir Work?

The mechanism by which favipiravir plays broad-spectrum antiviral activity has not yet been fully clarified, but the available evidence supports its ability to selectively inhibit RNA polymerase associated with influenza virus replication, which can be converted in the body into a biologically active phytol-5'-triphosphate inositol (favipiravir RTP). The favipiravir RTP structure is similar to that of radon, competing with viral RNA polymerases, causing it to be misidentified by viral RNA polymerase and inserted into the viral RNA chain or bound edited into the viral RNA polymerase domain, triggering fatal mutations and impeding the replication and transcription of viral RNA strands.
Side effects & Warning

Animal experiment data indicates that it may be teratogenic, which means that the drug may affect the growth and development of the baby, so pregnant women are excluded from clinical trials. But there is no clear evidence in human trials.Sed ultrices nisl velit, eu ornare est ullamcorper a. Nunc quis nibh magna. Proin risus erat, fringilla vel purus sit amet, mattis porta enim. Duis fermentum faucibus est, sed vehicula velit sodales vitae. Mauris mollis lobortis turpis, eget accumsan ante aliquam quis. Nam ullamcorper rhoncus sem vitae tempus. Curabitur ut tortor a orci fermentum ultricies. Mauris maximus velit commodo, varius ligula vel, consequat est. We have also found that the drug can cause elevated uric acid in the blood. Therefore, we need to ensure that the patient does not have gout and monitor the uric acid content in the patient's blood. There may also be some gastrointestinal side effects, but that's all. Noted: Favipiravir is only used when other antiviral drugs are not effective or effective. To sum up, Favipiravir is a new antiviral drug with precise efficacy and good safety mechanism, with good prospects.
COVID-2019: Status of Favipiravir in the world

China says: “Antiviral favipiravir effective against COVID-19”
Randomized trials of the broad-spectrum antiviral favipiravir, marketed as an anti-influenza treatment, have shown "obvious efficacy" against COVID-19, according to Zhang Xinmin, head of the China National Center for Biotechnology Development. Zhang's comments were reported by Xinhua News Agency, China's official state-run press agency.
In one trial, testing favipiravir with interferon in Shenzhen, results showed that patients treated with the combination had significantly reduced the duration of symptoms, as measured by viral load chest imaging, vs. a control group. In another study, clinical recovery rates were higher for COVID-19 patients treated with favipiravir vs. those in a control group.

Russia says: “Favipiravir(Avifavir) has been approved to treat COVID-2019”
Russia has approved an anti-influenza drug, Favipiravir, to treat Covid-19 and will start delivering it to hospitals this month, according to Russia’s sovereign wealth fund.
Preliminary trials appeared to show that it could shorten recovery times for patients with Covid-19. The final stage of Favipiravir clinical trials involving 330 patients are ongoing, RDIF and ChemRar said Monday, but patients are ongoing, RDIF and ChemRar said Monday, but Russia’s Ministry of Health on Saturday already temporarily approved the use of the drug as a coronavirus treatment.
favipiravir is Russia’s first Covid-19 drug and has shown high efficacy in treating patients with coronavirus during clinical trials. favipiravir has received a registration certificate from the Ministry of Health of the Russian Federation. Thus, favipiravir has become the first Favipiravir-based drug in the world approved for the treatment of Covid-19,” they said in the statement.

India says: "Glenmark Pharmaceuticals has gained an approval from India’s drug regulator for the antiviral drug favipiravir for the treatment of mild-to-moderate COVID-19 patients."
Glenmark Pharmaceuticals has gained an approval from India’s drug regulator for the antiviral drug favipiravir for the treatment of mild-to-moderate COVID-19 patients.Glenmark is now set to manufacture and market its favipiravir product under the brand name FabiFlu in India, and is the first oral favipiravir-approved medication in the country for the treatment of COVID-19.
The approval is based on clinical evidence of favipiravir demonstrating promising results in patients with mild-to-moderate COVID-19 disease. According to Glenmark, the drug offers rapid reduction in viral load with four days and provides faster symptomatic and radiological improvement. In addition, favipiravir demonstrated clinical improvement of up to 88% among those with a mild-to-moderate case of COVID-19.“FabiFlu has demonstrated an encouraging response in mild-to-moderate COVID-19 patients during clinical trials. Moreover, it is orally administered, and so it serves as a more convenient treatment option over other intravenously administered medications,” said Saldanha.
Glenmark has also announced its intention to conduct another clinical trial to evaluate the efficacy of favipiravir and another antiviral drug, umifenovir, as a combination therapy in moderate, hospitalised adult COVID-19 patients in India.

Attitudes from more countries on against COVID-2019 by Favipiravir
The US Department of Defense developed favipiravir in partnership with MediVector, Inc. as a broad-spectrum antiviral and sponsored it through FDA Phase II and Phase III clinical trials, where it demonstrated safety in humans and efficacy against the influenza virus.Despite demonstrating safety in more than 2,000 patients and showing accelerated clearance of influenza virus by 6 to 14 hours in the Phase III trials, favipiravir remains unapproved in the UK and the USA.
The Italian Pharmaceuticals Agency AIFA has approved testing antiviral drug favipiravir for the coronavirus, Health Minister Roberto Speranza said on Monday. The technical-scientific committee is developing a testing and research programme to assess the impact of the drug in the initial phases of the disease after an initial analysis of the available data on favipiravir.
Update the latest information in time!

[1] Koons C (7 August 2014). "Ebola Drug From Japan May Emerge Among Key Candidates". Bloomberg.com.
[2] Fink S (4 February 2015). "Ebola Drug Aids Some in a Study in West Africa". The New York Times.
[3] Lumby, Casper (3 March 2020). "Favipiravir and Zanamivir Cleared Infection with Influenza B in a Severely Immunocompromised Child". Clinical Infectious Diseases. Retrieved 5 May 2020.
[4] EJ Lane (June 22, 2016). "Fujifilm in Avigan API license with Zhejiang Hisun Pharmaceuticals". Fierce Pharma. Retrieved April 20, 2020.
[5]"Medicine registration license ЛП-006225". Government registry of medicines. Russian Ministry of Health. Retrieved May 30, 2020.